ImageneBio (NASDAQ:IMA) Posts Quarterly Earnings Results, Misses Estimates By $0.08 EPS

ImageneBio (NASDAQ:IMA) announced its quarterly earnings data on Monday. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.08), FiscalAI reports.

ImageneBio Trading Down 3.4%

NASDAQ IMA traded down $0.14 on Monday, hitting $3.97. 14,772 shares of the company’s stock were exchanged, compared to its average volume of 115,823. ImageneBio has a 52 week low of $3.88 and a 52 week high of $8.84. The stock has a market cap of $45.06 million, a price-to-earnings ratio of -0.87 and a beta of 0.83. The stock has a 50-day moving average of $4.53 and a 200-day moving average of $5.58.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on IMA shares. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a report on Friday, September 25th. HC Wainwright initiated coverage on ImageneBio in a report on Friday, August 21st. They issued a “buy” rating and a $28.00 price objective for the company. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $28.00.

Hedge Funds Weigh In On ImageneBio

Institutional investors and hedge funds have recently bought and sold shares of the company. Rangeley Capital LLC raised its position in shares of ImageneBio by 78.6% during the first quarter. Rangeley Capital LLC now owns 32,590 shares of the company’s stock worth $163,000 after acquiring an additional 14,346 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of ImageneBio during the 2nd quarter worth about $208,000. Renaissance Technologies LLC grew its stake in ImageneBio by 23.6% in the first quarter. Renaissance Technologies LLC now owns 81,696 shares of the company’s stock valued at $408,000 after acquiring an additional 15,600 shares during the period. Stonepine Capital Management LLC acquired a new stake in ImageneBio in the 2nd quarter valued at $539,044,000. Finally, BlackRock Inc. bought a new stake in shares of ImageneBio during the second quarter worth about $797,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples.

Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions.